Dentists in Manchester Center, VT Accepting Medicare
7 Dentists found. Showing 1 - 7
 Dr. Richard Frank Heilemann, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 74 Long View Drive, Manchester Center, VT 05254 Phone: 802-362-1099 Fax: 802-362-1901 |
Dr. Geoffry Lee Campe, D.D.S. Dentist - Orthodontics and Dentofacial Orthopedics Medicare: Not Enrolled in Medicare Practice Location: 107 Bonnet St, Manchester Center, VT 05255 Phone: 802-362-4833 Fax: 802-362-4833 |
Dr. John Ottesen, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 74 Longview Drive, Manchester Center, VT 05255 Phone: 315-761-5366 |
 Dr. Mary Corinne Squire, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 3429 Richville Rd, Manchester Center, VT 05255 Phone: 802-366-9119 Fax: 802-366-9099 |
Dr. Nicholas Maguire Guy, DMD Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 74 Longview Drive, Manchester Center, VT 05255 Phone: 802-768-9305 |
Dr. Philip Harold Ehret, DMD Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 39 Elm St, Manchester Center, VT 05255 Phone: 802-362-3636 |
Dr. Xandra H Velenchik, D.M.D. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 5053 Main Street, Manchester Center, VT 05255 Phone: 802-768-8595 Fax: 802-768-8595 |
News Archive
Dyax to use proceeds of public offering for commercialization and distribution activities of KALBITOR
Dyax Corp. today announced the pricing of an underwritten public offering of 17,000,000 shares of its common stock at a price to the public of $3.25 per share. The gross proceeds from the sale of shares, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $51.8 million. The offering is expected to close on or about March 30, 2010, subject to customary closing conditions.
Positive results from Palatin's bremelanotide Phase 2B trial on female sexual dysfunction
Palatin Technologies, Inc. today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD).
FDA accepts Avanir IND for AVP-923 to treat agitation in patients with AD
Avanir Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for the study of AVP-923, an investigational drug for the treatment of agitation in patients with Alzheimer's disease (AD).
Inhaled corticosteroids reduce COPD mortality risk
Patients with chronic obstructive pulmonary disease (COPD) who use inhaled corticosteroids may have a significantly decreased mortality risk, according to a new study published in the September issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP).
› Verified 8 days ago
Psychologists
Pharmacists
Clinical Social Workers
Counselors
Dentists
Occupational Therapists